Combined neutrophil-to-lymphocyte ratio and nomogram for predicting progression-free survival in recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors
BackgroundThe outlook for individuals dealing with metastatic or recurrent cervical cancer is still unfavorable, and existing biomarkers that assess the effectiveness of immune checkpoint inhibitors (ICIs) have certain drawbacks. Our objective was to a…